Iaso Therapeutics

Executive Summary

Iaso Therapeutics is a privately held biotechnology company based in Cambridge, MA, developing next-generation synthetic antigen vaccines using its proprietary mutant Qβ (mQβ) virus-like particle (VLP) platform. The platform is designed to enable rapid development, high immunogenicity, and improved stability, with a focus on broad-spectrum vaccines against infectious diseases, particularly to address antimicrobial resistance. Founded in 2020, the company is at an early stage, with no disclosed funding rounds or pipeline candidates yet in clinical development. Its technology aims to differentiate through the use of mutant Qβ VLPs as a scaffold for antigen display, potentially offering advantages over conventional vaccine platforms in terms of durability and breadth of immune response. The company's profile suggests it is actively advancing preclinical work, likely targeting bacterial and viral pathogens with high unmet need.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data for lead vaccine candidate40% success
• H2 2026Series A financing or strategic partnership35% success
• 2027IND filing for first vaccine candidate20% success